A randomised phase I study of etrolizumab (rhuMAb ß7) in moderate to severe ulcerative colitis.
Gut
; 62(8): 1122-30, 2013 Aug.
Article
en En
| MEDLINE
| ID: mdl-22717454
Palabras clave
Crohn's disease; Etrolizumab; IBD; IBD basic research; IBD clinical; IBD models; IBDgenetics; antibody targeted therapy; apoptosis; arthritis; autoimmune disease; cell cycle; cytokines; dendritic cells; drug development; genetics; immunology; inflammatory bowel disorders; integrins; pharmacokinetics; rhuMAb ß7; safety; signal transduction; ulcerative colitis
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Fármacos Gastrointestinales
/
Colitis Ulcerosa
/
Anticuerpos Monoclonales
Tipo de estudio:
Clinical_trials
/
Prognostic_studies
Límite:
Adolescent
/
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Año:
2013
Tipo del documento:
Article